Advanced search
Publication Cover
Expert Review of Precision Medicine and Drug Development
Personalized medicine in drug development and clinical practice
Volume 7, 2022 - Issue 1
Submit an article Journal homepage
441
Views
0
CrossRef citations to date
0
Altmetric
Editorial

Ramucirumab or merestinib in biliary tract cancer: new combinations, old mistakes?

Alessandro Rizzoa Struttura Semplice Dipartimentale di Oncologia Medica per la presa in carico globale del paziente oncologico “Don Tonino Bello, IRCCS Istituto Tumori “Giovanni Paolo II, Bari, ItalyCorrespondence[email protected]
View further author information
,
Alessandro Di Federicob Department of Experimental, Diagnostic and Specialty Medicine, S. Orsola-Malpighi University Hospital, Bologna, ItalyView further author information
,
Gennaro Palmiottia Struttura Semplice Dipartimentale di Oncologia Medica per la presa in carico globale del paziente oncologico “Don Tonino Bello, IRCCS Istituto Tumori “Giovanni Paolo II, Bari, ItalyView further author information
&
Giovanni Brandib Department of Experimental, Diagnostic and Specialty Medicine, S. Orsola-Malpighi University Hospital, Bologna, ItalyView further author information
Pages 60-61 | Received 15 Nov 2021, Accepted 27 Jun 2022, Published online: 30 Jun 2022

References

  • Rizvi S, Khan SA, Hallemeier CL, et al. Cholangiocarcinoma ‐ evolving concepts and therapeutic strategies. Nat Rev Clin Oncol. 2018;15(2):95‐111.
  • Valle J, Wasan H, Palmer DH, et al. ABC-02 trial investigators. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273–1281.
  • Kelley RK, Bridgewater J, Gores GJ, et al. Systemic therapies for intrahepatic cholangiocarcinoma. J Hepatol. 2020;72(2):353–363.
  • Rizzo A, Frega G, Ricci AD, et al. Anti-EGFR monoclonal antibodies in advanced biliary tract cancer: a systematic review and meta-analysis. Vivo. 2020Mar-Apr;34(2):479–488. PMID: 32111744; PMCID: PMC7157865.
  • Mahipal A, Kommalapati A, Tella SH, et al. Novel targeted treatment options for advanced cholangiocarcinoma. Expert Opin Investig Drugs. 2018Sep;27(9):709–720. Epub 2018 Aug 30. PMID: 30124336.
  • Rizzo A, Ricci AD, Brandi G. Pemigatinib: hot topics behind the first approval of a targeted therapy in cholangiocarcinoma. Cancer Treat Res Commun. 2021;27:100337. Epub 2021 Feb 18. PMID: 33611090.
  • Valle JW, Vogel A, Denlinger CS, et al. Addition of ramucirumab or merestinib to standard first-line chemotherapy for locally advanced or metastatic biliary tract cancer: a randomised, double-blind, multicentre, phase 2 study. Lancet Oncol. 2021;22(10):1468–1482.
  • Valle JW, Lamarca A, Goyal L, et al. New horizons for precision medicine in biliary tract cancers. Cancer Discov. 2017;7(9):943–962.
  • Banales JM, Marin JJG, Lamarca A, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020Sep;17(9):557–588. Epub 2020 Jun 30. PMID: 32606456; PMCID: PMC7447603.
  • Abou-Alfa GK, Sahai V, Hollebecque A, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 2020;21(5):671–684.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.